The last time I wrote on Novo Nordisk (NVO), it was with a Seeking Alpha article entitled "Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback." With respect to this article, I ...

Good morning, everyone, and welcome to our Viatris Investor event. I'm Bill Szablewski, Head of Capital Markets and Investor Relations. It's great to see everyone here in a full room today. Before we ...

To learn more about the CNBC CFO Council, visit cnbccouncils.com/cfo Nearly half of U.S. generic prescriptions originate in India, which relies on the Strait of ...

Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but ...

Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company plans to use an ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Out Of Order is a Java-based interactive game designed to test and improve the player's cognitive abilities. In this game, players are presented with a sequence of characters or numbers that are out ...

Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them. By Mark Miller Holly Kluck found a great price ...